ZFP91 Inhibitors
Chemical inhibitors of ZFP91 operate through various biochemical pathways to inhibit its function as an E3 ubiquitin ligase, which is crucial for tagging specific proteins for degradation by the proteasome. Proteasome inhibitors such as MG132, bortezomib (also known as Velcade), carfilzomib, ixazomib, and oprozomib, function by blocking the proteasome's ability to degrade ubiquitin-tagged proteins. This action results in the accumulation of these proteins within the cell, which can interfere with the normal turnover and regulation of proteins that ZFP91 targets. By preventing the degradation of these proteins, the inhibitors effectively blunt the regulatory role of ZFP91 in the ubiquitin-proteasome pathway. Peptide aldehyde compounds, such as Z-LLF-CHO, also fit into this category, as they can inhibit the proteasome, although they are less specific than the aforementioned inhibitors.
Other inhibitors such as PD 0332991, MLN4924, and MLN7243 target upstream processes that are indirectly related to the function of ZFP91. Palbociclib, which inhibits CDK4/6, may lead to reduced phosphorylation of the retinoblastoma protein, potentially impacting cell cycle progression and the cellular context within which ZFP91 operates. MLN4924 inhibits the NEDD8-activating enzyme, affecting the neddylation process that is essential for the activation of cullin-RING ubiquitin ligases (CRLs), which are protein complexes that ZFP91 may interact with. Inhibition of this process could disrupt ZFP91's ability to form functional ubiquitin ligase complexes. MLN7243, by inhibiting the ubiquitin-activating enzyme (UAE), blocks the very beginning of the ubiquitination process, which is necessary for ZFP91 to exert its function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor. ZFP91 has been implicated in cell cycle progression through its E3 ubiquitin ligase activity. By inhibiting CDK4/6, palbociclib may reduce the phosphorylation of the retinoblastoma protein, thus potentially hindering the cell cycle progression in which ZFP91 is involved, leading to its functional inhibition. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can prevent the degradation of ubiquitinated proteins. As ZFP91 functions as an E3 ubiquitin ligase, MG132 could lead to the accumulation of proteins that are normally targeted for degradation by ZFP91, thereby inhibiting the ubiquitin ligase function of ZFP91. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 is a NEDD8-activating enzyme inhibitor. By inhibiting this enzyme, the neddylation of cullin proteins is blocked, which is necessary for the function of cullin-RING ligases (CRLs). ZFP91 has been shown to interact with CRLs, and its inhibition could disrupt the function of ZFP91 by hindering its association with CRL complexes. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor, similar to MG132 but more clinically advanced. By inhibiting the proteasome, it leads to the buildup of proteins that are targeted for degradation. Since ZFP91 is an E3 ubiquitin ligase, bortezomib could inhibit ZFP91's function by preventing the turnover of its ubiquitin-conjugated substrates. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib is an oral proteasome inhibitor. It functions similarly to bortezomib, but with improved pharmacokinetics. It would inhibit ZFP91 by the same mechanism, leading to the accumulation of proteins that ZFP91 would normally help to degrade. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is another proteasome inhibitor, which would inhibit ZFP91 by preventing the proteasomal degradation of ubiquitinated proteins, potentially inhibiting the E3 ligase activity of ZFP91. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib is a selective and potent proteasome inhibitor. By blocking the proteasome, carfilzomib would inhibit the degradation of ubiquitin-tagged proteins, thereby inhibiting the function of ZFP91 as an E3 ubiquitin ligase. | ||||||
MLN7243 | 1450833-55-2 | sc-507338 | 5 mg | $340.00 | ||
MLN7243 is an inhibitor of the ubiquitin-activating enzyme (UAE). Since ZFP91's function relies on ubiquitination, MLN7243 could inhibit ZFP91 by blocking the initial step of the ubiquitination cascade, thereby preventing ZFP91 from tagging its substrates. | ||||||